Literature DB >> 32933761

Landmark trials in the medical oncology management of early stage breast cancer.

Whitney Hensing1, Cesar A Santa-Maria2, Lindsay L Peterson1, Jennifer Y Sheng3.   

Abstract

With the advent of breast cancer screening programs, the majorities of patients with newly diagnosed breast cancer are diagnosed with early stage disease and are likely to experience cure with proper treatment. Significant advances have been made in the management of early-stage breast cancer to personalize treatment according to disease biology. This progress has led to improvement in survival outcomes and quality of life for our patients. In this review, we discuss landmark clinical trials in medical oncology that have shaped the current standard of care for early stage ER-positive, HER2-positive, and triple negative breast cancer.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adjuvant; Breast cancer; Clinical trials; HER-2; Hormone receptor; Neoadjuvant trastuzumab; Pertuzumab; T-DM1; Trastuzumab emtansine; Triple negative

Year:  2020        PMID： 32933761      PMCID： PMC7655597          DOI： 10.1053/j.seminoncol.2020.08.001

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  90 in total

1.  Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Authors:  Sara M Tolaney; Hao Guo; Sonia Pernas; William T Barry; Deborah A Dillon; Lauren Ritterhouse; Bryan P Schneider; Fei Shen; Kit Fuhrman; Michele Baltay; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Mathew J Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth Overmoyer; Ann H Partridge; Clifford A Hudis; Ian E Krop; Harold J Burstein; Eric P Winer
Journal:  J Clin Oncol       Date:  2019-04-02       Impact factor: 44.544

Review 2.  Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Sukhbinder Dhesy-Thind; Glenn G Fletcher; Phillip S Blanchette; Mark J Clemons; Melissa S Dillmon; Elizabeth S Frank; Sonal Gandhi; Rasna Gupta; Mihaela Mates; Beverly Moy; Ted Vandenberg; Catherine H Van Poznak
Journal:  J Clin Oncol       Date:  2017-03-06       Impact factor: 44.544

3.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Authors:  Sara M Tolaney; William T Barry; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Matthew Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth A Overmoyer; Ann H Partridge; Hao Guo; Clifford A Hudis; Ian E Krop; Harold J Burstein; Eric P Winer
Journal:  N Engl J Med       Date:  2015-01-08       Impact factor: 91.245

4.  Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).

Authors:  Erik J Blok; Judith R Kroep; Elma Meershoek-Klein Kranenbarg; Marjolijn Duijm-de Carpentier; Hein Putter; Joan van den Bosch; Eduard Maartense; A Elise van Leeuwen-Stok; Gerrit-Jan Liefers; Johan W R Nortier; Emiel J Th Rutgers; Cornelis J H van de Velde
Journal:  J Natl Cancer Inst       Date:  2018-01-01       Impact factor: 13.506

5.  Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

Authors:  Norikazu Masuda; Soo-Jung Lee; Shoichiro Ohtani; Young-Hyuck Im; Eun-Sook Lee; Isao Yokota; Katsumasa Kuroi; Seock-Ah Im; Byeong-Woo Park; Sung-Bae Kim; Yasuhiro Yanagita; Shinji Ohno; Shintaro Takao; Kenjiro Aogi; Hiroji Iwata; Joon Jeong; Aeree Kim; Kyong-Hwa Park; Hironobu Sasano; Yasuo Ohashi; Masakazu Toi
Journal:  N Engl J Med       Date:  2017-06-01       Impact factor: 91.245

6.  Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.

Authors:  Patricia A Ganz; Edward H Romond; Reena S Cecchini; Priya Rastogi; Charles E Geyer; Sandra M Swain; Jong-Hyeon Jeong; Louis Fehrenbacher; Howard M Gross; Adam M Brufsky; Patrick J Flynn; Tanya A Wahl; Thomas E Seay; James L Wade; David D Biggs; James N Atkins; Jonathan Polikoff; John L Zapas; Eleftherios P Mamounas; Norman Wolmark
Journal:  J Clin Oncol       Date:  2017-10-26       Impact factor: 44.544

7.  Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial.

Authors:  John P Pierce; Loki Natarajan; Bette J Caan; Barbara A Parker; E Robert Greenberg; Shirley W Flatt; Cheryl L Rock; Sheila Kealey; Wael K Al-Delaimy; Wayne A Bardwell; Robert W Carlson; Jennifer A Emond; Susan Faerber; Ellen B Gold; Richard A Hajek; Kathryn Hollenbach; Lovell A Jones; Njeri Karanja; Lisa Madlensky; James Marshall; Vicky A Newman; Cheryl Ritenbaugh; Cynthia A Thomson; Linda Wasserman; Marcia L Stefanick
Journal:  JAMA       Date:  2007-07-18       Impact factor: 56.272

8.  Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.

Authors:  Eric Hahnen; Bianca Lederer; Jan Hauke; Sibylle Loibl; Sandra Kröber; Andreas Schneeweiss; Carsten Denkert; Peter A Fasching; Jens U Blohmer; Christian Jackisch; Stefan Paepke; Bernd Gerber; Sherko Kümmel; Christian Schem; Guido Neidhardt; Jens Huober; Kerstin Rhiem; Serban Costa; Janine Altmüller; Claus Hanusch; Holger Thiele; Volkmar Müller; Peter Nürnberg; Thomas Karn; Valentina Nekljudova; Michael Untch; Gunter von Minckwitz; Rita K Schmutzler
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

9.  Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

Authors:  Gunter von Minckwitz; Chiun-Sheng Huang; Max S Mano; Sibylle Loibl; Eleftherios P Mamounas; Michael Untch; Norman Wolmark; Priya Rastogi; Andreas Schneeweiss; Andres Redondo; Hans H Fischer; William Jacot; Alison K Conlin; Claudia Arce-Salinas; Irene L Wapnir; Christian Jackisch; Michael P DiGiovanna; Peter A Fasching; John P Crown; Pia Wülfing; Zhimin Shao; Elena Rota Caremoli; Haiyan Wu; Lisa H Lam; David Tesarowski; Melanie Smitt; Hannah Douthwaite; Stina M Singel; Charles E Geyer
Journal:  N Engl J Med       Date:  2018-12-05       Impact factor: 176.079

10.  Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.

Authors: 
Journal:  Lancet       Date:  2019-02-08       Impact factor: 79.321
View more
  2 in total

1.  Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer.

Authors:  Hanwen Wang; Chen Zhao; Cesar A Santa-Maria; Leisha A Emens; Aleksander S Popel
Journal:  iScience       Date:  2022-06-30

2.  The Impact of the Introduction of the Breast Unit Model in a Northwestern Italian Region.

Authors:  Laura Paleari; Federico Tassinari; Matteo Astengo; Daniela Amicizia; Chiara Paganino; Gabriella Paoli; Paolo Pronzato; Filippo Ansaldi
Journal:  Healthcare (Basel)       Date:  2022-08-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.